INMB Stock Analysis
IN
Uncovered
INmune Bio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.